IBO IMPACT BIOMEDICAL INC.
Pharmaceutical Preparations · NYSE · SEC CIK 1834105 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY103.7%
TTM EPS YoY184.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12,655.3%
Net margin4,247.4%
FCF margin—
EBITDA margin-9,657.9%
Returns
ROE—
ROA9.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.6%
Debt / equity0.00x
Current ratio0.04x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.07x
Accruals ratio8.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $32,000 | — | — | $50,000 |
| Cost of revenue | $424,000 | — | — | — |
| Gross profit | -$392,000 | — | — | — |
| R&D expense | $340,000 | $278,000 | $1.69M | $1.23M |
| SG&A expense | $873,000 | $718,000 | $315,000 | $325,000 |
| Operating income | -$4.28M | -$28.75M | -$4.03M | -$3.40M |
| Interest expense | $793,000 | $1.06M | $444,000 | $462,000 |
| Pretax income | -$14.45M | -$24.74M | -$4.41M | -$7.88M |
| Income tax | -$2.58M | $33,000 | — | -$621,000 |
| Net income | -$11.84M | -$24.71M | -$4.34M | -$7.25M |
| EBITDA | -$3.14M | -$27.63M | -$2.91M | -$2.29M |
| EPS (basic) | -0.38 | -2.30 | -0.07 | -0.10 |
| EPS (diluted) | -0.38 | -2.30 | -0.07 | -0.10 |
| Balance sheet | ||||
| Cash & equivalents | $3,000 | $2.00M | $1,000 | $2,000 |
| Receivables | $5,000 | $201,000 | $0 | — |
| Inventory | $63,000 | — | — | — |
| Current assets | $411,000 | $2.45M | $332,000 | $122,000 |
| PP&E, net | — | $17,000 | $287,000 | $276,000 |
| Goodwill | — | $25.09M | $25.09M | $25.09M |
| Intangibles | $16.99M | $17.81M | $18.92M | $20.03M |
| Total assets | $17.41M | $20.29M | $44.63M | $46.50M |
| Current liabilities | $1.16M | $9.79M | $13.14M | $10.59M |
| Total liabilities | $1.85M | $13.05M | $16.37M | $13.83M |
| Shareholders' equity | $12.31M | $4.26M | $25.22M | $29.56M |
| Shares outstanding | 8.29M | 11.50M | 10.00M | 70.50M |
| Cash flow statement | ||||
| Operating cash flow | -$1.89M | -$2.85M | -$2.85M | -$2.24M |
| Investing cash flow | $3,000 | $2,000 | -$15,000 | -$349,000 |
| Financing cash flow | -$109,000 | $4.85M | $2.87M | $2.55M |
| Depreciation & amortization | $1.15M | $1.12M | $1.12M | $1.11M |
| Stock-based compensation | $13,000 | $19,000 | — | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.